121 related articles for article (PubMed ID: 34318905)
1. Dihydrotanshinone exerts antitumor effects and improves the effects of cisplatin in anaplastic thyroid cancer cells.
Allegri L; Domenis R; Navarra M; Celano M; Russo D; Capriglione F; Damante G; Baldan F
Oncol Rep; 2021 Sep; 46(3):. PubMed ID: 34318905
[TBL] [Abstract][Full Text] [Related]
2. Effects of Dihydrotanshinone I on Proliferation and Invasiveness of Paclitaxel-Resistant Anaplastic Thyroid Cancer Cells.
Allegri L; Capriglione F; Maggisano V; Damante G; Baldan F
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360846
[TBL] [Abstract][Full Text] [Related]
3. Nobiletin Alone or in Combination with Cisplatin Decreases the Viability of Anaplastic Thyroid Cancer Cell Lines.
Sousa DP; Pojo M; Pinto AT; Leite V; Serra AT; Cavaco BM
Nutr Cancer; 2020; 72(2):352-363. PubMed ID: 31287730
[No Abstract] [Full Text] [Related]
4. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
[TBL] [Abstract][Full Text] [Related]
5. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
Yan P; Su Z; Zhang Z; Gao T
Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract][Full Text] [Related]
7. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
8. miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.
Sheng W; Chen Y; Gong Y; Dong T; Zhang B; Gao W
Oncol Rep; 2016 Dec; 36(6):3387-3396. PubMed ID: 27779717
[TBL] [Abstract][Full Text] [Related]
9. CRSP8 promotes thyroid cancer progression by antagonizing IKKα-induced cell differentiation.
Liao Y; Hua Y; Li Y; Zhang C; Yu W; Guo P; Zou K; Li W; Sun Y; Wang R; Zuo Y; Sui S; Tian C; Hao J; Chen M; Hu S; Chen M; Long Q; Wang X; Zou L; Xie F; Guo W; Deng W
Cell Death Differ; 2021 Apr; 28(4):1347-1363. PubMed ID: 33162555
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
[TBL] [Abstract][Full Text] [Related]
11. Regulation of autophagy by miR-30d impacts sensitivity of anaplastic thyroid carcinoma to cisplatin.
Zhang Y; Yang WQ; Zhu H; Qian YY; Zhou L; Ren YJ; Ren XC; Zhang L; Liu XP; Liu CG; Ming ZJ; Li B; Chen B; Wang JR; Liu YB; Yang JM
Biochem Pharmacol; 2014 Feb; 87(4):562-70. PubMed ID: 24345332
[TBL] [Abstract][Full Text] [Related]
12. Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.
Pinto N; Prokopec SD; Vizeacoumar F; Searle K; Lowerison M; Ruicci KM; Yoo J; Fung K; MacNeil D; Lacefield JC; Leong HS; Mymryk JS; Barrett JW; Datti A; Boutros PC; Nichols AC
PLoS One; 2018; 13(11):e0207152. PubMed ID: 30419054
[TBL] [Abstract][Full Text] [Related]
13. Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells.
Allegri L; Baldan F; Mio C; Puppin C; Russo D; Kryštof V; Damante G
Oncol Rep; 2016 Apr; 35(4):2413-8. PubMed ID: 26884249
[TBL] [Abstract][Full Text] [Related]
14. Effects of melatonin on the toxicity and proliferation of human anaplastic thyroid cancer cell line.
Ghorbani-Anarkooli M; Dabirian S; Zendedel A; Moladoust H; Bahadori MH
Acta Histochem; 2021 Apr; 123(3):151700. PubMed ID: 33667778
[TBL] [Abstract][Full Text] [Related]
15. Diterpenoid anthraquinones as chemopreventive agents altered microRNA and transcriptome expressions in cancer cells.
Su YS; Kuo MZ; Kuo YT; Huang SW; Lee CJ; Su ZY; Ni YH; Li DK; Wu TY
Biomed Pharmacother; 2021 Apr; 136():111260. PubMed ID: 33465676
[TBL] [Abstract][Full Text] [Related]
16. Identification of dihydrotanshinone I as an ERp57 inhibitor with anti-breast cancer properties via the UPR pathway.
Shi W; Han H; Zou J; Zhang Y; Li H; Zhou H; Cui G
Biochem Pharmacol; 2021 Aug; 190():114637. PubMed ID: 34062127
[TBL] [Abstract][Full Text] [Related]
17. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
[TBL] [Abstract][Full Text] [Related]
18. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Wang W; Zhou J; Zhao L; Chen S
Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
[TBL] [Abstract][Full Text] [Related]
19. Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation.
Liu J; Feng L; Zhang H; Zhang J; Zhang Y; Li S; Qin L; Yang Z; Xiong J
Cancer Biol Ther; 2018 Jun; 19(6):484-496. PubMed ID: 29504819
[TBL] [Abstract][Full Text] [Related]
20. Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2.
Wang C; Zhang R; Tan J; Meng Z; Zhang Y; Li N; Wang H; Chang J; Wang R
Oncol Rep; 2020 May; 43(5):1491-1502. PubMed ID: 32323855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
